TPD3310
/ Taibidi Pharmaceutical Technology
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 27, 2026
A Study of TPD3310 in Patients With Advanced Malignant Tumors
(clinicaltrials.gov)
- P1 | N=112 | Not yet recruiting | Sponsor: TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.
First-in-human • New P1 trial • Cholangiocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Lung Cancer • Renal Cell Carcinoma • Solid Tumor • EGFR • MET
July 21, 2026
A Study of TPD3310 in Patients With Advanced Malignant Tumors
(clinicaltrials.gov)
- P1 | N=112 | Recruiting | Sponsor: TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD. | Not yet recruiting ➔ Recruiting
Enrollment open • First-in-human • Cholangiocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • EGFR • MET
1 to 2
Of
2
Go to page
1